{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:47Z","timestamp":1781632487100,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most first-line antiretroviral therapy (ART) regimes in Sub-Saharan Africa contain tenofovir disoproxil fumarate (TDF) which has a nephrotoxic potential. Baseline renal function assessment is not feasible in many settings and therefore not required prior to starting ART according to Malawian guidelines. We assessed renal function over 36 months in people living with HIV (PLHIV) starting TDF-based ART at Lighthouse Clinic, Lilongwe, Malawi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on demographics, medical history, laboratory values, WHO stage, and anthropometric measures were collected at study entry and during visits at 1, 3, 6 months, and every 6 months until month 36. The main outcome of the study was renal function, defined by the estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation. Descriptive statistics and multivariable linear regression analysis were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A baseline creatinine value was available for 1,430 PLHIV (57% female, mean age\u2009\u00b1\u2009SD 36.0\u2009\u00b1\u20099.3 years). Of these, 443 PLHIV (62% female) were observed until month 36. Factors associated with changes in eGFR over time included baseline log-transformed eGFR (coefficient\u2009=\u2009\u22120.787;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), MAP at baseline, and initial WHO clinical HIV stage. The overall trend in eGFR categories indicated a shift towards lower classes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large cohort of PLHIV, TDF did not result in a decline in eGFR. Indeed, an unexpected trend of improved renal function was observed. Even though findings need to be interpreted with caution due to considerable attrition, our results suggest TDF can be administered safely in resource-limited settings where ART decisions are frequently made without pre-treatment renal assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12675-2","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:04:09Z","timestamp":1769627049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal function during tenofovir\u2011based antiretroviral therapy among people living with HIV in Lilongwe, Malawi: findings from the prospective LighTen cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3391-934X","authenticated-orcid":false,"given":"Melani R.","family":"Mahanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-1597","authenticated-orcid":false,"given":"Florian","family":"Neuhann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-5707","authenticated-orcid":false,"given":"Ethel","family":"Rambiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Nhlema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-1273","authenticated-orcid":false,"given":"Hannock","family":"Tweya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8711-8008","authenticated-orcid":false,"given":"Myo","family":"Chit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chiwoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thom","family":"Chaweza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9180-0850","authenticated-orcid":false,"given":"Claudia","family":"Wallrauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4626-0592","authenticated-orcid":false,"given":"Tom","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-1145","authenticated-orcid":false,"given":"Volker","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-3549","authenticated-orcid":false,"given":"Hans-Michael","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"12675_CR1","unstructured":"World Health Organization. Epidemiological fact sheet: HIV statistics, globally and by WHO region. Geneva: World Health Organization. 2023."},{"key":"12675_CR2","unstructured":"World Health Organisation. HIV\/AIDS [Internet]. WHO | Regional Office for Africa. 2024 [cited 2024 Aug 30]. Available from: https:\/\/www.afro.who.int\/health-topics\/hivaids"},{"issue":"7","key":"12675_CR3","doi-asserted-by":"publisher","first-page":"e0131353","DOI":"10.1371\/journal.pone.0131353","volume":"10","author":"R Granich","year":"2015","unstructured":"Granich R, Gupta S, Hersh B, Williams B, Montaner J, Young B, et al. Trends in AIDS Deaths, new infections and ART coverage in the top 30 countries with the highest AIDS mortality Burden; 1990\u20132013. PLoS ONE. 2015;10(7):e0131353.","journal-title":"PLoS ONE"},{"issue":"9","key":"12675_CR4","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830\u20139.","journal-title":"N Engl J Med"},{"key":"12675_CR5","unstructured":"World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. World Health Organization; 2010."},{"issue":"4","key":"12675_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"key":"12675_CR7","doi-asserted-by":"crossref","unstructured":"Shivakumar YM, Burra E, Shahid K, Tamene Y, Mody SP, Sadiq KO, et al. Tenofovir-induced renal dysfunction among HIV-infected patients: a systematic review. Cureus. 2023;15(9).","DOI":"10.7759\/cureus.45787"},{"issue":"5","key":"12675_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/hiv.13019","volume":"22","author":"R Hsu","year":"2021","unstructured":"Hsu R, Brunet L, Fusco J, Beyer A, Prajapati G, Wyatt C, et al. Risk of chronic kidney disease in people living with HIV by Tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. HIV Med. 2021;22(5):325\u201333.","journal-title":"HIV Med"},{"issue":"2","key":"12675_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/hiv.12982","volume":"22","author":"A Poda","year":"2021","unstructured":"Poda A, Kabore N, Malateste K, De Rekeneire N, Semde A, Bikinga Y, et al. Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa cohort collaboration. HIV Med. 2021;22(2):113\u201321.","journal-title":"HIV Med"},{"issue":"13","key":"12675_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/QAD.0b013e32834957da","volume":"25","author":"A Brennan","year":"2011","unstructured":"Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on Tenofovir. AIDS. 2011;25(13):1603.","journal-title":"AIDS"},{"issue":"24","key":"12675_CR11","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMra1508467","volume":"377","author":"SD Cohen","year":"2017","unstructured":"Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. N Engl J Med. 2017;377(24):2363\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"12675_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-023-00801-1","volume":"20","author":"NE Diana","year":"2024","unstructured":"Diana NE, Naicker S. The changing landscape of HIV-associated kidney disease. Nat Rev Nephrol. 2024;20(5):330\u201346.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"12675_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrneph.2009.141","volume":"5","author":"J Fabian","year":"2009","unstructured":"Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol. 2009;5(10):591\u20138.","journal-title":"Nat Rev Nephrol"},{"key":"12675_CR14","unstructured":"Ministry of Health and Population of Malawi. Clinical management of HIV in children and adults [Internet]. 2022. Available from: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/Malawi-Clinical-HIV-Guidelines-2022-edition-5.pdf"},{"issue":"9","key":"12675_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrneph.2013.143","volume":"9","author":"P Delanaye","year":"2013","unstructured":"Delanaye P, Mariat C. The applicability of eGFR equations to different populations. Nat Rev Nephrol. 2013;9(9):513\u201322.","journal-title":"Nat Rev Nephrol"},{"key":"12675_CR16","unstructured":"Ministry of Health, Malawi. Malawi Population-based HIV Impact Assessment 2020\u20132021 [Internet]. 2022. Available from: https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2022\/12\/241122_Mphia_Foreword.pdf"},{"key":"12675_CR17","unstructured":"Ministry of Health, Malawi. Malawi Integrated Clinical HIV Guidelines 1st Edition 2011 [Internet]. 2011. Available from: https:\/\/dms.hiv.health.gov.mw\/dataset\/malawi-integrated-clinical-hiv-guidelines-1st-edition-2011"},{"key":"12675_CR18","unstructured":"Ministry of Health and Population, Malawi. Clinical Management of HIV in Children and Adults [Internet]. 2018. Available from: https:\/\/dms.hiv.health.gov.mw\/dataset\/a9aeb081-8f02-4590-9aea-a004cd813550\/resource\/9d9be092-143a-43f6-8c24-eb83a7281553"},{"key":"12675_CR19","unstructured":"Department of HIV & AIDS. Malawi guidelines for clinical management of HIV in children and adults. 2nd ed. Ministry of Health, Lilongwe; 2014."},{"key":"12675_CR20","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"European Society of Cardiology","year":"2018","unstructured":"European Society of Cardiology. ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"6","key":"12675_CR21","doi-asserted-by":"publisher","first-page":"e0130453","DOI":"10.1371\/journal.pone.0130453","volume":"10","author":"N Glaser","year":"2015","unstructured":"Glaser N, Deckert A, Phiri S, Rothenbacher D, Neuhann F. Comparison of various equations for estimating GFR in malawi: how to determine renal function in resource limited settings? PLoS ONE. 2015;10(6):e0130453.","journal-title":"PLoS ONE"},{"issue":"6","key":"12675_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2215\/CJN.06870909","volume":"5","author":"WM Michels","year":"2010","unstructured":"Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, Age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"12675_CR23","doi-asserted-by":"publisher","first-page":"e0184766","DOI":"10.1371\/journal.pone.0184766","volume":"12","author":"A Deckert","year":"2017","unstructured":"Deckert A, Neuhann F, Klose C, Bruckner T, Beiersmann C, Haloka J, et al. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia. PLoS ONE. 2017;12(9):e0184766.","journal-title":"PLoS ONE"},{"issue":"7","key":"12675_CR24","doi-asserted-by":"publisher","first-page":"e41011","DOI":"10.1371\/journal.pone.0041011","volume":"7","author":"DC Johnson","year":"2012","unstructured":"Johnson DC, Chasela C, Maliwichi M, Mwafongo A, Akinkuotu A, Moses A, et al. Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-Na\u00efve individuals in Lilongwe, Malawi. PLoS ONE. 2012;7(7):e41011.","journal-title":"PLoS ONE"},{"issue":"7","key":"12675_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/0956462417749733","volume":"29","author":"B Chikwapulo","year":"2018","unstructured":"Chikwapulo B, Ngwira B, Sagno JB, Evans R. Renal outcomes in patients initiated on Tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi. Int J STD AIDS. 2018;29(7):650\u20137.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"12675_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12882-015-0192-4","volume":"16","author":"DR Chadwick","year":"2015","unstructured":"Chadwick DR, Sarfo FS, Kirk ESM, Owusu D, Bedu-Addo G, Parris V, et al. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol. 2015;16(1):195.","journal-title":"BMC Nephrol"},{"issue":"4","key":"12675_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ckj\/sfv041","volume":"8","author":"S Waheed","year":"2015","unstructured":"Waheed S, Attia D, Estrella MM, Zafar Y, Atta MG, Lucas GM, et al. Proximal tubular dysfunction and kidney injury associated with Tenofovir in HIV patients: a case series. Clin Kidney J. 2015;8(4):420\u20135.","journal-title":"Clin Kidney J"},{"key":"12675_CR28","doi-asserted-by":"crossref","unstructured":"Debeb SG, Muche AA, Kifle ZD, Sema FD. Tenofovir disoproxil fumarate-associated renal dysfunction among adult people living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: a comparative retrospective cohort study. HIV\/AIDS-Research and Palliative Care. 2021;491\u2013503.","DOI":"10.2147\/HIV.S308339"},{"issue":"8","key":"12675_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ekir.2019.04.024","volume":"4","author":"S Doshi","year":"2019","unstructured":"Doshi S, Ucanda M, Hart R, Hou Q, Terzian AS, Subramanian T, et al. Incidence and risk factors for renal disease in an outpatient cohort of HIV-Infected patients on antiretroviral therapy. Kidney Int Rep. 2019;4(8):1075\u201384.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"12675_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40780-024-00343-z","volume":"10","author":"H Yagura","year":"2024","unstructured":"Yagura H, Watanabe D, Nakauchi T, Kushida H, Hirota K, Nishida Y, et al. Association between Tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years Tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients. J Pharm Health Care Sci. 2024;10(1):20.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"12675_CR31","doi-asserted-by":"publisher","first-page":"e00681","DOI":"10.1002\/prp2.681","volume":"11","author":"F Kalemeera","year":"2023","unstructured":"Kalemeera F, Godman B, Stergachis A, Rennie T. Effect of Tenofovir containing ART on renal function in patients with moderate\/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia. Pharmacol Res Perspect. 2023;11(1):e00681.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"12675_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-019-0227-1","volume":"16","author":"TJ Mtisi","year":"2019","unstructured":"Mtisi TJ, Ndhlovu CE, Maponga CC, Morse GD. Tenofovir-associated kidney disease in africans: a systematic review. AIDS Res Therapy. 2019;16(1):12.","journal-title":"AIDS Res Therapy"},{"issue":"10","key":"12675_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/cid\/ciu117","volume":"58","author":"L Mulenga","year":"2014","unstructured":"Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, et al. Effect of baseline renal function on Tenofovir-Containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58(10):1473\u201380.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12675_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/QAI.0000000000003232","volume":"94","author":"AO Reis","year":"2023","unstructured":"Reis AO, Rocco Suassuna JH, Cunha CB, Portela EN, Veloso VG, Grinszteijn B, et al. Evaluation of glomerular filtration rate trends in people living with HIV corrected by the baseline glomerular filtration rate. JAIDS J Acquir Immune Defic Syndr. 2023;94(1):82.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"12675_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","volume":"39","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633\u201345.","journal-title":"Immunity"},{"issue":"12","key":"12675_CR36","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1086\/652749","volume":"201","author":"J Neuhaus","year":"2010","unstructured":"Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of Inflammation, Coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788\u201395.","journal-title":"J Infect Dis"},{"issue":"1","key":"12675_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1186\/s12879-024-09594-5","volume":"24","author":"J Choshi","year":"2024","unstructured":"Choshi J, Hanser S, Mabhida SE, Mokoena H, Moetlediwa MT, Muvhulawa N, et al. A systematic review assessing the association of inflammatory markers with kidney dysfunction in people living with HIV on highly active antiretroviral therapy. BMC Infect Dis. 2024;24(1):776.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"12675_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12882-024-03537-7","volume":"25","author":"DR Chadwick","year":"2024","unstructured":"Chadwick DR, Barker F, Smith C, Perditer O, Hardy Y, Owusu D, et al. Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003\u20132018. BMC Nephrol. 2024;25(1):241.","journal-title":"BMC Nephrol"},{"issue":"10","key":"12675_CR39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/QAD.0000000000001807","volume":"32","author":"FJJ Palella","year":"2018","unstructured":"Palella FJJ, Li X, Gupta SK, Estrella MM, Phair JP, Margolick JB, et al. Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men. AIDS. 2018;32(10):1247.","journal-title":"AIDS"},{"issue":"1","key":"12675_CR40","doi-asserted-by":"publisher","first-page":"e0002648","DOI":"10.1371\/journal.pgph.0002648","volume":"4","author":"M Ngongondo","year":"2024","unstructured":"Ngongondo M, Ritz J, Hughes MD, Matoga M, Hosseinipour MC, on behalf of the AIDS Clinical Trials Group A5208 A. Discontinuation of Tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: an analysis of data from four multi-country clinical trials. PLOS Global Public Health. 2024;4(1):e0002648.","journal-title":"PLOS Global Public Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12675-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:17:10Z","timestamp":1781630230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12675-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12675"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12675-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Lighthouse Tenofovir cohort study (LighTen, Clinical Trial number NCT02381275) was approved by Ethical Committees of the universities of Cologne (No. 14\u2013251) and Heidelberg (No. S-293\/2014) and the National Health Research Commission, Ministry of Health, Malawi (NHSRC Protocol #1199).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}